Capital World Investors lifted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 408.6% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 18,025,301 shares of the life sciences company's stock after purchasing an additional 14,481,232 shares during the quarter. Capital World Investors owned about 11.37% of Illumina worth $2,408,721,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Versant Capital Management Inc increased its stake in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after purchasing an additional 146 shares during the period. Golden State Wealth Management LLC purchased a new position in Illumina during the 4th quarter valued at about $32,000. Assetmark Inc. grew its holdings in Illumina by 954.8% during the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after buying an additional 296 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new position in Illumina in the 4th quarter valued at about $45,000. Finally, Lee Danner & Bass Inc. acquired a new stake in shares of Illumina during the 4th quarter worth about $48,000. Hedge funds and other institutional investors own 89.42% of the company's stock.
Illumina Stock Performance
ILMN stock opened at $71.21 on Friday. The company has a market capitalization of $11.27 billion, a P/E ratio of -9.27, a PEG ratio of 1.60 and a beta of 1.38. The company has a quick ratio of 1.42, a current ratio of 1.77 and a debt-to-equity ratio of 0.63. The company has a 50-day simple moving average of $84.61 and a 200 day simple moving average of $120.40. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.
Illumina (NASDAQ:ILMN - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Sell-side analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Several analysts have commented on ILMN shares. Canaccord Genuity Group lowered their target price on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Stephens reissued an "overweight" rating and issued a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a report on Friday, February 7th. TD Cowen downgraded shares of Illumina from a "buy" rating to a "hold" rating and lowered their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. Finally, HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target for the company. in a research note on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $138.70.
View Our Latest Stock Report on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for May 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
